NCT00099931已完成3 期
Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 254
- 试验地点
- 1
- 主要终点
- Change from baseline in HbA1c at 24 weeks
研究概览
简要总结
Many people with type 2 diabetes cannot maintain their target blood glucose levels on a single therapy. The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, in lowering overall blood glucose levels when added to insulin in people with type 2 diabetes who are not at target blood glucose levels on insulin alone.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Blood glucose criteria must be met
- •On a stable dose of insulin as defined by the protocol
- •Body mass inde (BMI) in the range 22-45
排除标准
- •Type 1 diabetes
- •Pregnancy or lactation
- •Evidence of serious diabetic complications
- •Evidence of serious cardiovascular complications
- •Laboratory value abnormalities as defined by the protocol
- •Other protocol defined exclusion criteria may apply
结局指标
主要结局
Change from baseline in HbA1c at 24 weeks
次要结局
- Change from baseline in fasting plasma glucose at 24 weeks
- Adverse event profile after 24 weeks of treatment
- Change from baseline in mean daily insulin dose at 24 weeks
- Change from baseline in mean daily number of insulin injections at 24 weeks
- Patients with endpoint <7% after 24 weeks
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Drug Naive Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT00101803Novartis Pharmaceuticals527
已完成
3 期
Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT00099944Novartis Pharmaceuticals515
已完成
3 期
Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT00099853Novartis Pharmaceuticals362
已完成
3 期
Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT00099892Novartis Pharmaceuticals544
已完成
3 期
Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT00106340Novartis Pharmaceuticals3,118